Clinical Trials Logo

Obsessive-Compulsive Disorder clinical trials

View clinical trials related to Obsessive-Compulsive Disorder.

Filter by:

NCT ID: NCT04335175 Completed - Clinical trials for Obsessive-Compulsive Disorder

Sensory Symptoms in Tourette Syndrome and Obsessive-Compulsive Disorder

SenST-Plus
Start date: April 14, 2020
Phase:
Study type: Observational

This study seeks to address two key questions related to sensory dysregulation in Tourette syndrome (TS) and obsessive compulsive disorder (OCD): 1) Is sensory dysregulation in OCD clinically distinct from that in TS? 2) To what extent does sensory dysregulation affect QOL in each of these disorders? Patients with TS, patients with OCD, and healthy controls will complete an online battery of validated questionnaires assessing sensory dysregulation, psychiatric symptoms, and quality of life.

NCT ID: NCT04323566 Enrolling by invitation - Schizophrenia Clinical Trials

Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement

Ra-P-OCD
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or -behavior (OCB) where there is an indication of immune system involvement. The secondary objectives of this study are 1. To assess whether Rituximab treatment (with the doses and timing described below) as compared to placebo is associated with amelioration in psychiatric symptomatology 2. To assess whether Rituximab treatment as compared to placebo is associated with improvement in executive functions 3. To assess whether Rituximab treatment as compared to placebo is associated with amelioration in neurological symptoms 4. To evaluate the longevity of psychiatric, neurological and executive improvements associated with Rituximab treatment for up to 16 months after the first infusion (i.e. 12 months after the last infusion) 5. To evaluate whether Rituximab treatment as described is safe for these patients. The exploratory objectives of this study are 1. To assess changes in blood and cerebrospinal fluid (CSF) markers for immune activity associated with Rituximab treatment compared to placebo 2. To assess statistical associations between biological markers in blood or CSF and clinical response 3. To describe changes in somatic symptoms associated with treatment with Rituximab vs placebo for patients with initial symptoms in the questionnaires 4. To describe changes on MR and EEG associated with treatment with Rituximab vs placebo for patients with initial pathology in these examination 5. To study immune mechanisms coupled with psychiatric symptoms, possibly identifying novel biomarkers with potential for subtyping encephalopathies with immune engagement, using biobank cells, blood and CSF samples collected from the participants.

NCT ID: NCT04313439 Completed - Clinical trials for Obsessive-Compulsive Disorder

Targeting Taboo Thoughts In Obsessive-Compulsive Disorder

Start date: March 26, 2020
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to investigate if a cognitive treatment targeting obsessive beliefs in patients with aggressive obsessions is feasible and effective as an online treatment.

NCT ID: NCT04286126 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

Neuroimaging Biomarkers for Predicting rTMS Response in OCD

Start date: January 15, 2021
Phase: N/A
Study type: Interventional

This study evaluates an accelerated schedule of theta-burst stimulation using a Transcranial Magnetic Stimulation (TMS) device for treatment-resistant Obsessive Compulsive Disorder (OCD). In a randomized fashion, half the participants will receive accelerated theta-burst stimulation at the dorsomedial prefrontal cortex (DMPFC), while half will receive accelerated theta-burst stimulation at the right orbitofrontal (rOFC) site.

NCT ID: NCT04283812 Withdrawn - Parkinson Disease Clinical Trials

New Stereotactic Frame System for Neurosurgery

Start date: January 2023
Phase: N/A
Study type: Interventional

This study is designed to demonstrate an in-house developed re-attachable stereotactic system that can markedly reduce the overall deep brain stimulation (DBS) procedure time to greatly facilitate subject access to neurosurgical restorative therapies. Subjects will consist exclusively of individuals who have been approved to undergo deep brain stimulation surgery for the treatment of a neurological disorder at Mayo Clinic - Rochester MN. This study is a quantitative comparative, between-subject study enrolling approximately 10 subjects.

NCT ID: NCT04281134 Active, not recruiting - Clinical trials for Obsessive-Compulsive Disorder

Development of Adaptive Deep Brain Stimulation for OCD

Phase Ib
Start date: October 11, 2019
Phase: N/A
Study type: Interventional

This research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and distressing thoughts (obsessions) and irresistible repetitive behaviors. OCD affects 2-3% of the US population, and is responsible for substantial functional impairment and increased risk of early death. The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure/response prevention and certain medications. About 30-40% of patients fail to respond and few experience complete symptom resolution. Up to 25% of patients have difficulty tolerating CBT and the risk of relapse after therapies remains large. For the most severe cases, neurosurgery (surgery in the brain), has long been the option of last resort. In this study the investigators want develop an adaptive Deep Brain Stimulation (aDBS) system to use in subjects with intractable (hard to control) OCD. Deep brain stimulation remains investigational for OCD patients and is not considered standard therapy. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed deep brain stimulation may restore balance to dysfunctional brain circuitry implicated in OCD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for OCD treatment. This current research protocol will focus on the completion of Phase Ib which will implant the RC+S system in 2 subjects.

NCT ID: NCT04228744 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

The Efficacy and Mechanism of DBS in VIC and NAcc for Refractory OCD

Start date: January 10, 2020
Phase: N/A
Study type: Interventional

This study will evaluate the efficacy and explore the mechanism of deep brain stimulation (DBS) in the ventral internal capsule (VIC) and nucleus accumbens (NAc) for refractory obsessive-compulsive disorder (OCD).

NCT ID: NCT04225624 Recruiting - Clinical trials for Major Depressive Disorder

Improving Attentional and Cognitive Control in the Psychological Treatment of Intrusive Thoughts

Start date: April 30, 2021
Phase: N/A
Study type: Interventional

The investigators are conducting this study to learn more about the cognitive and attentional processes among individuals with three types of repetitive negative thinking (RNT): mental rituals (as seen in obsessive compulsive disorder, OCD), worries (as seen in generalized anxiety disorder, GAD), and ruminations (as seen in major depressive disorder, MDD). Specifically, the investigators are studying whether psychological treatment can help people with RNT who have trouble stopping unwanted thoughts and shifting their attention.

NCT ID: NCT04217408 Active, not recruiting - Clinical trials for Obsessive-Compulsive Disorder

Deep Brain Stimulation (DBS) for the Treatment of Refractory Obsessive-compulsive Disorder (OCD)

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Deep brain stimulation for treatment resistant deep brain stimulation

NCT ID: NCT04215549 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

The Cost of Obsessive-compulsive Disorder (OCD) in China

OCD
Start date: January 2, 2020
Phase:
Study type: Observational

The purpose of this study is to estimate the cost of obsessive-compulsive disorder in China based on the prevalence rate from a social perspective.